From:aacr.org The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine therapy. The U.S. Food and Drug Administration (FDA) has approved imlunestrant (Inluriyo) for the treatment of adult patients with advanced or metastatic breast cancer that expresses the estrogen receptor (ER), does not overexpress human epidermal growth factor receptor 2 (HER2), …
Study Suggests Next-Generation Breast Cancer Drug Can Overcome Resistance
From: genomeweb.com New details about a key mechanism underlying treatment resistance in breast cancer are reported this week in Science Translational Medicine, along with data suggesting that a new type of targeted therapy can overcome the mutations driving this resistance. Most breast cancer tumors express estrogen receptor-alpha (ER-alpha), a transcription factor that can drive cancer cell growth and the target …
ELAINE-2 Trial Could Establish the Actionability of ESR1 in HR+/HER2- Breast Cancer
By: Caroline Seymour From: onclive.com The ongoing ELAINE-2 trial (NCT04432454), which is evaluating the combination of lasofoxifene and abemaciclib (Verzenio) in patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer, is building on findings from the ELAINE study, which demonstrated that the oral selective estrogen receptor modulator (SERM) has significant preclinical antitumor activity in ESR1-mutant models, said Matthew P. …